Video

Dr. Kaufman hails autologous muscle-derived cells as "transformational" SUI treatment

Author(s):

Urology Times staff

“This technology is truly a transformational opportunity for urology,” says Melissa R. Kaufman, MD, PhD, FACS.

Current Time 0:00
Duration 3:13
Loaded: 5.10%
Stream Type LIVE
Remaining Time 3:13
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    In this video, Melissa R. Kaufman, MD, PhD, FACS, discusses autologous muscle derived cells for urinary sphincter repair (AMDC-USR) and how this technology is designed to treat stress urinary incontinence (SUI) in female patients. Kaufman is a professor of urology and chief of the division of reconstructive urology and pelvic health at Vanderbilt University, Nashville, Tennessee.

    Related Videos
    Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
    Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
    Considerations for patient follow-up after onabotA administration
    Considerations for patient follow-up after onabotA administration
    Administering onabotA: Improving patient comfort and easing anxiety
    Administering onabotA: Improving patient comfort and easing anxiety
    Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
    Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
    Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © - bongkarn - stock.adobe.com
    Experts discuss expanding use of vibegron for OAB
    Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
    Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
    Karyn S. Eilber, MD, answers a question during a Zoom video interview
    Karyn S. Eilber, MD, on patient counseling for onabotA treatment for OAB
    Woman at doctor | Image Credit: © rocketclips - stock.adobe.com
    Optimizing onabotA for OAB: What are some common misconceptions?
    Ruchika Talwar, MD, on how urologists can get involved in advocacy
    Ruchika Talwar, MD, on how urologists can get involved in advocacy
    Closeup of patient with prescription | Image Credit: © gpointstudio - stock.adobe.com
    Investigators characterize vibegron prescribing patterns for OAB
    Related Content
    Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI
    May 16th 2025

    Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI

    Melissa Kaufman, MD, PhD, FACS Hannah Clarke
    The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.
    Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause
    April 28th 2025

    Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause

    Melissa Kaufman, MD, PhD, FACS
    In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.
    Artificial urinary sphincter for SUI shows safety, efficacy in prospective study
    May 9th 2025

    Artificial urinary sphincter for SUI shows safety, efficacy in prospective study

    Melissa Kaufman, MD, PhD, FACS Hannah Clarke
    "This trial will be the benchmark for research reporting in the future," says Melissa R. Kaufman, MD, PhD, FACS.
    Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
    March 21st 2022

    Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

    Urology Times staff
    “This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
    First patient enrolled in trial of Voro Urologic Scaffold for post-prostatectomy SUI
    April 24th 2025

    First patient enrolled in trial of Voro Urologic Scaffold for post-prostatectomy SUI

    Hannah Clarke
    "What is truly exciting is the potential for this device to meaningfully improve early and long-term continence rates, which can profoundly impact a patient's recovery and overall quality of life,” says Patrick Daily, MD.
    Neuromodulation device shows promising efficacy for neurogenic bladder
    April 16th 2025

    Neuromodulation device shows promising efficacy for neurogenic bladder

    Hannah Clarke
    Data from the pivotal CONTINENCE trial showed encouraging efficacy of SCONE neuromodulation therapy.
    © 2025 MJH Life Sciences

    All rights reserved.